Akimitsu Maeda

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 4

Top Topics

Chemotherapy Induced

Electronic Health Record

Top Venues

European journal of clinical pharmacology

Cancer chemotherapy and pharmacology

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Investigational new drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Akimitsu Maeda, Kyoko Hori, Yumiko Sone, Naoya Hashimoto, Kosaku Uchida
Assessing floor contamination by antineoplastic agents in a Japanese medical institution specializing in cancer treatment. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
Akimitsu Maeda, Hitoshi Ando, Nobuyuki Katakami, Naoya Hashimoto, Jun-Ichi Morishige, Shoji Fukushima, Akira Okada, Hiromichi Ebi, Masahide Matsuzaki, Hiroji Iwata, Masataka Sawaki
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. European journal of clinical pharmacology 78 (8) (2022)
Akimitsu Maeda, Kei Irie, Naoya Hashimoto, Shoji Fukushima, Hitoshi Ando, Akira Okada, Hiromichi Ebi, Masaki Kajita, Hiroji Iwata, Masataka Sawaki
Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. Investigational new drugs 39 (1) (2020)
Akimitsu Maeda, Kei Irie, Hitoshi Ando, Ayako Hasegawa, Hiroya Taniguchi, Shigenori Kadowaki, Kei Muro, Masahiro Tajika, Masahiro Aoki, Kazuhide Inaguma, Masaki Kajita, Akio Fujimura, Shoji Fukushima
Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms. Cancer chemotherapy and pharmacology 83 (1) (2018)